Brivudine-13C, 15N2

Brivudine-13C, 15N2 (Bromovinyldeoxyuridine-13C, 15N2) is 13C and 15N labeled Brivudine. Brivudine is a thymidine analogue with antiviral activity, indicated for the early treatment of acute herpes zoster.

Product Specifications

Product Name Alternative

Bromovinyldeoxyuridine-13C, 15N2; BVDU-13C, 15N2

UNSPSC

12352005

Target

CMV; Isotope-Labeled Compounds

Related Pathways

Anti-infection; Others

Applications

COVID-19-anti-virus

Field of Research

Infection; Cancer

Smiles

O=[13C]1[15N](C=C(C([15NH]1)=O)/C=C/Br)[C@@H]2O[C@@H]([C@H](C2)O)CO

Molecular Formula

C10 13CH13Br 15N2O5

Molecular Weight

336.11

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Rabasseda X, et al. Brivudine: a herpes virostatic with rapid antiviral activity and once-daily dosing. Drugs Today (Barc) . 2003 May;39 (5) :359-71.|[3]Keam SJ, et al. Brivudin (bromovinyl deoxyuridine) . Drugs. 2004;64 (18) :2091-7; discussion 2098-9.